Literature DB >> 17071293

Nasal polyposis: prevalence of positive food and inhalant skin tests.

Melanie M Collins1, Sean Loughran, Pauline Davidson, Janet A Wilson.   

Abstract

OBJECTIVES: To investigate the etiology of nasal polyps and its relationship to allergy. The prevalence of positive food and inhalant skin tests in patients with nasal polyps and nonatopic controls was compared. STUDY DESIGN AND
SETTING: Prospective controlled study in tertiary referral rhinology clinic.
RESULTS: Seventy percent (70%) of the patients with nasal polyps had positive skin tests to an average of four foodstuffs, compared to 34 percent of controls (P = 0.006). Only 35 percent of the nasal polyp patients also had positive inhalant skin tests. Overall, the prevalence of positive inhalant skin tests was similar in the nasal polyp patients and controls.
CONCLUSIONS: These findings suggest that the positive skin tests to foods are not merely a reflection of the general atopic status of patients with nasal polyps. It may be that non-IgE-mediated hypersensitivities, such as to ingested foods, play a role on the basis of a significant number of patients with positive intradermal skin tests to foods. SIGNIFICANCE: Evaluation of the allergic status of patients with polyposis is important. Dietary manipulation may be indicated, though its role needs further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17071293     DOI: 10.1016/j.otohns.2006.07.005

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  Chronic rhinosinusitis as a multifactorial inflammatory disorder.

Authors:  Stella Lee; Andrew P Lane
Journal:  Curr Infect Dis Rep       Date:  2011-04       Impact factor: 3.725

2.  International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis.

Authors:  Sarah K Wise; Sandra Y Lin; Elina Toskala; Richard R Orlandi; Cezmi A Akdis; Jeremiah A Alt; Antoine Azar; Fuad M Baroody; Claus Bachert; G Walter Canonica; Thomas Chacko; Cemal Cingi; Giorgio Ciprandi; Jacquelynne Corey; Linda S Cox; Peter Socrates Creticos; Adnan Custovic; Cecelia Damask; Adam DeConde; John M DelGaudio; Charles S Ebert; Jean Anderson Eloy; Carrie E Flanagan; Wytske J Fokkens; Christine Franzese; Jan Gosepath; Ashleigh Halderman; Robert G Hamilton; Hans Jürgen Hoffman; Jens M Hohlfeld; Steven M Houser; Peter H Hwang; Cristoforo Incorvaia; Deborah Jarvis; Ayesha N Khalid; Maritta Kilpeläinen; Todd T Kingdom; Helene Krouse; Desiree Larenas-Linnemann; Adrienne M Laury; Stella E Lee; Joshua M Levy; Amber U Luong; Bradley F Marple; Edward D McCoul; K Christopher McMains; Erik Melén; James W Mims; Gianna Moscato; Joaquim Mullol; Harold S Nelson; Monica Patadia; Ruby Pawankar; Oliver Pfaar; Michael P Platt; William Reisacher; Carmen Rondón; Luke Rudmik; Matthew Ryan; Joaquin Sastre; Rodney J Schlosser; Russell A Settipane; Hemant P Sharma; Aziz Sheikh; Timothy L Smith; Pongsakorn Tantilipikorn; Jody R Tversky; Maria C Veling; De Yun Wang; Marit Westman; Magnus Wickman; Mark Zacharek
Journal:  Int Forum Allergy Rhinol       Date:  2018-02       Impact factor: 3.858

3.  Different roles of Staphylococcus aureus enterotoxin in different subtypes of nasal polyps.

Authors:  Ke-Jia Cheng; Shen-Qing Wang; Ying-Ying Xu
Journal:  Exp Ther Med       Date:  2016-12-02       Impact factor: 2.447

Review 4.  The Role of IgE Production in the Pathophysiology of Rhinitis and Rhinosinusitis.

Authors:  Elizabeth K Hoddeson; Sarah K Wise
Journal:  Curr Allergy Asthma Rep       Date:  2011-06       Impact factor: 4.806

5.  Correlation between clinical findings and eosinophil/neutrophil ratio in patients with nasal polyps.

Authors:  S Hancer Tecimer; F Kasapoglu; U L Demir; O A Ozmen; H Coskun; O Basut
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-07-10       Impact factor: 2.503

Review 6.  Risk Factors and Comorbidities in Chronic Rhinosinusitis.

Authors:  Derrick Tint; Stephanie Kubala; Elina Toskala
Journal:  Curr Allergy Asthma Rep       Date:  2016-02       Impact factor: 4.806

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.